Chemotherapeutic Combinations

DRUG3 trials

Sponsors

Mashhad University of Medical Sciences, Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital

Conditions

Advanced MelanomaAntibody-drug ConjugatesEsophageal NeoplasmsHER2Targeted TherapymCRC

Phase 2

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

Mashhad University of Medical SciencesEsophageal Neoplasms

Start: 2016-07-22End: 2018-12-30Target: 100Updated: 2017-08-22

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Peking University Cancer Hospital & InstituteAdvanced Melanoma

Start: 2019-03-23End: 2022-09-30Target: 145Updated: 2019-04-17

MA-CRC-II-016 SHR-1811

Not yet recruitingNCT07355764

Peking Union Medical College HospitalAntibody-drug Conjugates, HER2, mCRC +1

Start: 2025-12-30End: 2028-01-31Target: 80Updated: 2026-01-21